{"id":"autologous-cd7-targeting-car-t-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This therapy involves extracting T cells from a patient, genetically engineering them to express a chimeric antigen receptor (CAR) that targets CD7 (a surface antigen on T cells), and reinfusing the modified cells to recognize and eliminate CD7+ malignant T cells. CD7 is highly expressed on T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas, making it an attractive target for CAR T cell therapy.","oneSentence":"Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:48.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"T-cell acute lymphoblastic leukemia (T-ALL)"},{"name":"Peripheral T-cell lymphomas"}]},"trialDetails":[{"nctId":"NCT07280494","phase":"PHASE1","title":"To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-18","conditions":"CD7+ T-ALL/LBL","enrollment":18},{"nctId":"NCT07244380","phase":"PHASE2","title":"Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2025-11-28","conditions":"T Lymphoblastic Leukemia/Lymphoma","enrollment":38},{"nctId":"NCT07143929","phase":"PHASE1","title":"To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-18","conditions":"CD7 Positive R/R PTCL","enrollment":18},{"nctId":"NCT07139600","phase":"","title":"Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2024-08-01","conditions":"Aplastic Anaemia, CAR-T, CD7 Positive","enrollment":5},{"nctId":"NCT06758713","phase":"PHASE1","title":"Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Southern Medical University","startDate":"2025-01-15","conditions":"Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy","enrollment":60},{"nctId":"NCT06136364","phase":"PHASE1","title":"CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study","status":"RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2023-08-15","conditions":"T-lymphoblastic Lymphoma, T-ALL","enrollment":9},{"nctId":"NCT05513612","phase":"PHASE1","title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","status":"WITHDRAWN","sponsor":"Shanghai Pudong Hospital","startDate":"2020-08-01","conditions":"Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM)","enrollment":""},{"nctId":"NCT05528887","phase":"PHASE1","title":"Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2021-09-16","conditions":"Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma","enrollment":10},{"nctId":"NCT04785833","phase":"NA","title":"CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2021-03-04","conditions":"T-ALL","enrollment":20},{"nctId":"NCT04480788","phase":"PHASE1","title":"CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2020-11-24","conditions":"T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Autologous CD7-targeting CAR T cells","genericName":"Autologous CD7-targeting CAR T cells","companyName":"Hebei Senlang Biotechnology Inc., Ltd.","companyId":"hebei-senlang-biotechnology-inc-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies. Used for T-cell acute lymphoblastic leukemia (T-ALL), Peripheral T-cell lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}